drug · small molecule
APREPITANT
Marketedupdated 5mo agoby $HOTH Hoth Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 18 investigational indications.
targets
Substance-P receptor
all catalysts(1)
Trials studying APREPITANT
- phase2Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
- phase3A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
- phase2Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
- phase2Phase 2 Bunionectomy HTX-011 Administration Study
- phase3Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
- phase3To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
- phase3Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
- phase2Topical Aprepitant in Prurigo Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 26, 2027
357 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (31)
- Sep 18, 2035formulationUS 10500208
- Sep 18, 2035formulationUS 10500208
- Sep 18, 2035method-of-use (U-3440)US 10624850
- Sep 18, 2035method-of-use (U-2161)US 10624850
- Sep 18, 2035method-of-use (U-2161)US 10953018
- Sep 18, 2035method-of-use (U-3440)US 10953018
- Sep 18, 2035formulationUS 11173118
- Sep 18, 2035formulationUS 11173118
- Sep 18, 2035formulationUS 11744800
- Sep 18, 2035formulationUS 11744800
- Sep 18, 2035method-of-use (U-3787)US 11878074
- Sep 18, 2035formulationUS 12115254
- Sep 18, 2035formulationUS 12115254
- Sep 18, 2035formulationUS 12115255
- Sep 18, 2035formulationUS 12115255
- Sep 18, 2035formulationUS 12290520
- Sep 18, 2035formulationUS 12290520
- Sep 18, 2035formulationUS 9561229
- Sep 18, 2035formulationUS 9561229
- Sep 18, 2035method-of-use (U-3440)US 9808465
- Sep 18, 2035method-of-use (U-2161)US 9808465
- Sep 18, 2035formulationUS 9974742
- Sep 18, 2035formulationUS 9974742
- Sep 18, 2035formulationUS 9974793
- Sep 18, 2035formulationUS 9974793
- Sep 18, 2035formulationUS 9974794
- Sep 18, 2035formulationUS 9974794
- Sep 26, 2027formulationUS 8258132357d
- Sep 26, 2027formulationUS 8258132357d
- Sep 26, 2027formulationUS 8258132357d
- Sep 26, 2027formulationUS 8258132357d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that